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Organoids are self-organizing cellular 
structures that are grown in vitro from 
pluripotent stem cells (PSCs) or multi-
potent tissue-resident adult stem cells 
(ASCs). They mimic various aspects and 
functions of the respective tissue, and 
therefore are valuable models to study 
organ development and human diseases.[1] 
In addition, organoids provide a valu-
able tissue source for diverse biomedical 
applications such as drug screening and 
toxicology studies,[2–7] and in combina-
tion with genome editing tools might 
open up avenues for ex vivo gene therapy 
approaches.[8,9]
One of the first established and best 
studied organoid systems are murine 
small intestinal organoids grown from 
tissue resident ASCs.[10] When embedded 
in tumor-derived basement membrane 
extract (BME) (provided as the commer-
cial product Matrigel or CultrexBME2) 
and supplemented with growth factors 
that mimic the intestinal stem cell niche 
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(R-spondin, noggin, EGF), single Lgr5 positive (Lgr5+) stem 
cells grow into organoids. In a first phase they form spherical 
cysts that mainly consist of proliferating progenitor cells, and 
after ≈2–4 days they further transform into complex 3D struc-
tures with multiple outward-pointing buds. These crypt-like 
domains contain the cell types that normally reside in small 
intestinal crypts, including Lgr5+ stem cells, and the core 
domain of the organoid mainly contains the cell types that nor-
mally line the villi of the intestinal epithelium.[10,11] Since orga-
noids can be regrown after mechanical or enzymatic dissocia-
tion, the system allows rapid and seemingly indefinite expan-
sion of intestinal stem cells and primary intestinal epithelium 
in vitro. Adaptations of the growth factor cocktail also allow the 
growth of epithelial organoids from various other murine and 
human tissues.[12]
The establishment of organoid culture protocols critically 
depended on the use of the 3D scaffold BME.[10,13–17] This 
hydrogel consists of a heterogeneous mixture of extracellular 
matrix (ECM) proteins, proteoglycans, and growth factors 
secreted from Engelbreth–Holm–Swarm murine sarcomas.[18] 
The xenogeneic components and batch-to-batch variations 
strongly limit the use of cells grown in this matrix for clinical 
applications such as regenerative medicine and high-content 
screening.[18–20] In addition, due to the heterogeneous composi-
tion, precise modulation of physical and biochemical properties 
is not possible.[21] Hence there is a strong interest in finding 
defined substitutes to BME, and recently researchers developed 
polyethylene glycol (PEG)-based gels that mimic some of the 
features of BME.[22,23]
Here we designed a defined fibrin-based hydrogel that sup-
ports long-term expansion of epithelial organoids derived from 
different mouse and human tissues. We characterized the 
required mechanical and biological properties of the hydrogel, 
and studied the forces that organoids exert on the matrix at dif-
ferent stages of their growth. Our findings provide insights into 
organoid morphogenesis and organoid–ECM interactions, and 
provide a basis for the development of clinical-grade organoid 
protocols for future applications in regenerative medicine.
In our attempt to generate a defined matrix for culturing 
organoids, we first searched for a hydrogel that fulfills the phys-
ical requirements to support organoid growth. For this pur-
pose, we tested whether known well-defined and biocompatible 
matrices support organoid growth when supplemented with an 
amount of BME that is high enough to provide the required 
biological signals, but too low to provide significant mechanical 
support. We selected four different scaffolds that span a wide 
range of biological, physical, and chemical characteristics. A 
fully synthetic transglutaminase (TG) cross-linked and neu-
trally charged polyethylene glycol (PEG) gel,[24] a semisynthetic 
TG cross-linked and highly negatively charged hyaluronan 
(HA) gel,[25] a natural calcium cross-linked and highly nega-
tively charged alginate gel,[26] and a human-derived thrombin 
cross-linked fibrin gel that harbors both positive and negative 
charges (overall pI 5.5).[27] Since we reasoned that organoids 
require space for their increase in size during growth, we gen-
erated either degradable or deformable versions of these hydro-
gels: the PEG and HA gels contained the matrix metallopro-
teinase (MMP) sensitive peptide sequence GPQGIWGQ[28,29] 
integrated in their cross-linker, the alginate gel was weakly 
cross-linked with a method known to enable cell infiltration 
despite insensitivity to protease degradation,[26,30] and fibrin 
hydrogels are inherently degradable by proteases.
The gelation protocols of the four different hydrogels were 
first fine-tuned in order to obtain rheological properties sim-
ilar to BME (Figure S1, Supporting Information). We then 
performed an organoid formation assay (Figure 1A–D), and 
seeded a cell suspension of mouse small intestinal epithe-
lial cells into the different hydrogels, with or without 10% v/v 
BME supplementation. The frequency of cyst formation from 
single intestinal stem cells after three days (colony formation 
efficiency) was equally high in the fibrin gel supplemented 
with 10% v/v BME as in pure BME. In fibrin alone as well as 
the other tested hydrogels, colony formation efficiencies were 
significantly lower. In addition, when the rounded cysts were 
allowed to grow for eight days in the fibrin/BME hydrogel, 
they formed the crypt-like budding structures that are typical 
for murine small intestinal organoids (Figure 1E). We therefore 
concluded that fibrin provides an appropriate physical support 
for organoid cultures, but that biological signaling from one or 
several of the BME components is necessary for proper growth.
To further optimize the physical properties of the fibrin-
based hydrogel for intestinal organoid culturing, we next 
modulated the stiffness of the gel by varying the concentration 
of fibrin (Figure 2A). Using the colony formation assay, we 
found that fibrin concentrations between 1.5 and 6 mg mL−1, 
which correspond to stiffness between 24 ± 10 Pa (SD, n = 6) 
and 270 ± 8 Pa (SD, n = 3), allowed efficient formation of round 
cysts (Figure 2B,F). Increasing the fibrin concentration to 
7.5 mg mL−1, which generates a hydrogel with a stiffness of 
492 ± 78 Pa (SD, n = 3), led to the formation of dense sphe-
roids that did not continue to grow into budding organoids. 
The lower fibrin concentration of 1.5 mg mL−1 on the other 
hand resulted in gel degradation already after four days, and 
therefore also impaired organoid expansion (Figure 2C). We 
conclude that fibrin hydrogels between 3 and 4.5 mg mL−1 
(77 ± 25 Pa (SD, n = 3) and 140 ± 47 Pa (SD, n = 4)) provide the 
best physical properties for organoid expansion.
To further compare the physical properties of the fibrin-
based hydrogel and BME, we measured the pore sizes of the 
two scaffolds. Since both matrices are protein based, we used 
fluorescein-succinimidyl ester (F-NHS) to fluorescently label 
their backbones and analyzed the microstructures by confocal 
imaging. Consistent with scanning electron microscopy anal-
ysis,[31,32] we found that while BME generates a dense network 
with pores smaller than the resolution limit (estimated around 
200 nm with confocal imaging), fibrin generates a sparse web 
of thick fibers with a pore size of ≈4 µm (Figure 2E). Analysis of 
the fibrin-based hydrogel supplemented with 10% BME further 
demonstrates that the mixed hydrogel consists of a sparse net-
work of fibrin fibers filled with a thin mesh of BME (Figure 2E).
A recently developed protocol that allows the expansion 
of intestinal stem cells in a functionalized PEG gel demon-
strated that RGD motifs are required for intestinal stem cell 
proliferation.[22] As these domains occur naturally in fibrin, 
we speculated that integrin binding to RGD is also one of the 
key requirements for organoid growth in fibrin-based gels. 
To test this hypothesis, we performed the organoid formation 
assay with soluble RGD peptides as a competitive inhibitor to 
Adv. Mater. 2018, 30, 1801621
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extracellular matrix RGD binding (Figure 2D). We found that 
upon addition of soluble RGD organoid formation was inhib-
ited, suggesting that RGD domains on the matrix are necessary 
for organoid growth. Of note, laminin, one of the main com-
ponents of Matrigel, also contains RGD sites. However, while 
fibrin at 3 mg mL−1 provides a concentration of ≈35 × 10−6 m,[33] 
10% Matrigel only provides a concentration of ≈0.7 × 10−6 m, 
which might be too low to provide a biological effect.
Finally, we asked if increasing RGD densities on the scaffold 
further enhances organoid growth. Via factor XIII-mediated 
anchoring we coupled additional RGD ligands to the 3 mg mL−1 
fibrin matrix, while keeping its mechanical properties constant. 
We found that doubling or tripling the RGD densities neither 
affected the colony number nor the organoid morphology, 
suggesting that the natural RGD concentration on fibrin 
is sufficient for optimally promoting organoid growth (Figure S2, 
Supporting Information).
The dependency of organoid growth on RGD binding 
sites on the scaffold prompted us to investigate the mechan-
ical forces that organoids exert on the matrix. After stem 
cell seeding, when organoids form spherical cysts, they are 
thought to adapt this shape by building up internal pres-
sure via ion channel-mediated fluid influx.[34] Whether orga-
noids form buds because the crypt-like structures pull on the 
matrix to protrude out of the organoid core (invasive collective 
cell migration), or because the organoid core becomes more 
contractile and as a consequence the internal hydrostatic pres-
sure pushes the buds out (spatial differences in contractility), 
is however not known.[35] To answer this question, we analyzed 
the force distribution of growing organoids in the fibrin-based 
hydrogel with 3D traction force microscopy. We therefore 
tagged the fibrin matrix with TG modified fluorescent polysty-
rene nanoparticles, which anchor to fibrin during gelation and 
allow tracking of gel deformations. In our experimental setup, 
Adv. Mater. 2018, 30, 1801621
Figure 1. A) Scheme of seeding assay showing the hydrogel inside a silicone mold on a glass cover slip. Small intestinal stem cells first grow as 
cystic spheres as seen at day 3 (D3) followed by the formation of budding organoids after approximately one week. B) Quantifications of colony 
formation efficiency of mouse small intestinal stem cells in different hydrogel backbones with or without supplementation with 10% Matrigel. Data 
are expressed as a percentage of the colony count in Matrigel (100%). Error bars: SD, n = 5. C,D) Representative brightfield images of the cultures in 
the different hydrogels and Matrigel control. Scale bars: 200 µm. E) Budding organoids as seen in Matrigel and in fibrin + 10% Matrigel after 8 days. 
Scale bars: 100 µm.
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we first imaged the organoid during growth, then killed the 
organoid by adding sodium azide to the medium to relax the 
active cell forces, and finally imaged the same position again. 
Custom Matlab scripts (link provided in the Experimental Sec-
tion) were subsequently used to track the matrix deformations 
in 3D and to reconstruct the cellular forces. Since we used the 
equations of mechanics for linear elastic materials under small 
deformations, which are only valid as a first approximation, 
our results should be considered an estimate rather than a 
quantitative measurement of the cell forces.
We observed that rounded cystic organoids initially devel-
oping from intestinal stem cells typically exerted a nearly spher-
ical pressure on their matrix, consistent with expected active 
fluid uptake through ion pumping (Figure 3A). After initial 
cystic expansion, mouse small intestinal organoids start to form 
villus-like structures that mimic the in vivo architecture of the 
small intestinal epithelium. Interestingly, when we analyzed 
the forces generated by these asymmetrically growing orga-
noids, we observed that the organoids still push on the matrix 
at the crypt-like domains, but start to pull on the gel around 
the central lumen (core domain) (Figure 3B,C). Since intestinal 
stem cells reside in the crypt-like domains of the organoids,[10] 
and since stem-cell rich early cystic organoids usually adopt 
a spherical morphology, our measurements suggest that the 
morphogenesis of budding organoids is due to the presence of 
differentiated cells with higher contractility. This results in the 
invagination of the core domain, and outward protrusion of 
the less contractile stem-cell rich areas under the influence of 
internal pressure.
Cell contractility is usually mediated by the actin cytoskeleton 
and molecular motors.[35] We therefore searched for an inde-
pendent confirmation of this hypothesis by looking at F-actin 
Adv. Mater. 2018, 30, 1801621
Figure 2. A) Storage Modulus of fibrin hydrogels with different fibrin concentrations. Error bars: SD, n = 3. B) Number of cystic or dense mouse small 
intestinal organoids four days after seeding in fibrin gels of different stiffness supplemented with 10% Matrigel. Error bars: SD, n = 6. C) Size of cystic 
organoids four days after seeding in different concentrations of fibrin gels supplemented with 10% Matrigel. Error bars: SEM n = 67/65/74/66/3. 
D) Effect of soluble RGD peptides on the colony formation efficiency of mouse small intestinal stem cells in fibrin-based hydrogels (3 mg mL−1 
fibrin + 10% Matrigel). Error bars: SD, n = 4. E) FITC staining of Matrigel, Fibrin gels and Fibrin gels supplemented with 10% Matrigel showing 
the different microstructures. Scale bars: 20 µm. F) Representative brightfield images of mouse small intestinal organoids in fibrin gels of different 
stiffnesses after four days. Scale bar: 100 µm.
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distribution in budding organoids. 3D surface views and single 
plane close-up views showed that cells in the core regions but 
not in the crypt-like regions contained a shell of basal actin, 
between the nucleus and the outer membrane (Figure 3D). 
On the apical side, there was little to no cytoplasmic F-actin in 
either region, except for the well-known dense F-actin pillars 
supporting the microvilli. This pattern appeared consistently 
on all imaged organoids, and resulted in a large quantitative 
difference of basal actin distribution between core domains 
and cyst-like domains of organoids (Figure 3E).
We next aimed to identify the component of BME that pro-
vides the biological signals required for organoid growth in the 
fibrin matrix. We therefore supplemented the fibrin hydrogel 
with the main ECM components of BME: collagen IV, heparin (a 
glycosaminoglycan that mimics heparan sulfate proteoglycans), 
and the laminin-111/entactin complex (hereinafter referred to as 
laminin). To compensate for a potential loss of functionality of the 
purified components, we generated hydrogels with a final concen-
tration of the additives at least twice as high as in 10% BME. The 
heparin was modified chemically to be TG cross-linkable, in order 
to ensure retention in the fibrin gels. Laminin and collagen IV 
are large proteins known to self-assemble into an insoluble matrix 
in physiological conditions and were therefore kept unmodified. 
While neither supplementation with collagen IV nor with heparin 
supported organoid formation in our assay, the colony formation 
efficiency in fibrin gels supplemented with laminin was compa-
rable to that in pure BME (p = 0.15) (Figure 4A,B). In addition, 
when allowed to grow for longer periods, organoids also formed 
the crypt-like structures that are typical for murine small intestinal 
organoids (Figure 5A). To further identify the optimal laminin con-
centration for organoid formation and growth, we next performed 
the colony formation assay with fibrin gels supplemented with 
different amounts of laminin. While laminin concentrations of 
0.5 mg mL−1 already led to stem cell proliferation and formation 
of rounded cysts, further increasing the concentrations enhanced 
the colony formation efficiencies. At 2 mg mL−1, the organoid 
formation efficiency and phenotype were similar to pure BME 
(Figure 4C; Figure S3, Supporting Information).
To next assess if small intestinal organoid colonies in fibrin/
laminin gels grow from Lgr5+ stem cells, we isolated green 
fluorescent protein (GFP) positive cells from an organoid line 
that contains a Lgr5-GFP reporter by FACS, and seeded them 
Adv. Mater. 2018, 30, 1801621
Figure 3. A–C) Representative 3D traction force microscopy measurements of a cystic, an early budding and a late budding organoid (from left to right). 
Normal pressures (i.e., normal vector * stress tensor * normal vector) are color-displayed on the surface of the segmented organoids, and the white 
arrows are the local displacements of the matrix amplified threefold. Gradations on the bounding box are 100 µm. D) Surface view of a representative 
late budding organoid stained with phalloidin (actin) and Hoechst (nuclei) using Imaris software, with single-plane close-ups of the marked areas, 
highlighting basal actin machinery in the core-like domains but not the cyst-like domains. Main gradations on the bounding box are 40 µm. E) Quanti-
fication of the surface area between the nucleus and the basal membrane, as well as the density and total amount of F-actin in this area (basal actin), 
for cells located in crypt-like domains (as shown in close-up (b)) or core domains (as shown in close-up (c)). Values are the averages ± SEM over 107 
crypt cells and 128 core cells from five different organoids, with only cells lying horizontal in the imaging plane used for quantification.
www.advmat.dewww.advancedsciencenews.com
1801621 (6 of 12) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
into the hydrogel. Like in BME, individual GFP positive cells 
formed clusters, which further developed into cystic organoids 
(Figure S4, Supporting Information). Finally, we also inves-
tigated if organoid lines can be directly established in fibrin/
laminin gels from small intestinal crypts. Crypts were freshly 
isolated from Lgr5-GFP mice, and seeded into fibrin/laminin. 
Importantly, the organoid formation from isolated crypts was 
comparable to BME (Figure S5, Supporting Information).
To test if the defined fibrin/laminin hydrogel supports long- 
term expansion of murine small intestinal organoids, we 
passaged organoids in the gel for more than two months 
(>12 passages). Like organoids grown in pure BME, orga-
noids grown in fibrin/laminin maintained their typical archi-
tecture, with crypt-like structures pointing outwards from the 
central lumen (Figure 5A). These organoids were also posi-
tive for the epithelial cell marker E-cadherin, contained Lgr5+ 
stem cells and Paneth cells in the crypt-like domains, and had 
goblet and entero endocrine cells scattered throughout the orga-
noid structure (Figure 5A). To test whether the fibrin/laminin 
hydrogel is also applicable to other types of epithelial organoid 
cultures, we cultured human organoid lines derived from the 
small intestinal epithelium, liver, pancreas, and pancreatic 
ductal adenocarcinoma (PDAC) (Figure 5B). Of note, since 
human laminin shares 96% homology with mouse laminin 
(from UniProt sequence alignment), we used murine laminin 
also for expanding human organoid cultures. The pheno-
type of human liver and pancreas organoids was analyzed by 
immunocytochemistry, and like those grown in BME, expressed 
the ductal marker cytokeratin-19 (CK19) and progenitor marker 
SOX-9 (Figure 5C; Figure S6, Supporting Information). Orga-
noids, moreover, expressed the epithelial markers E-cadherin 
and β-catenin, as well as the marker Ki-67, demonstrating that 
the cells were in a proliferative state (Figure S6, Supporting 
Information). In addition, gene expression levels of pancreatic 
and liver organoid specific markers were quantified by qPCR, 
and no difference was observed between organoids grown in 
BME and fibrin/laminin (Figure S7, Supporting Information). 
To further test for functional differences between organoids 
grown in the different hydrogels, we performed a drug assay with 
the pancreatic cancer drugs gemcitabine and paclitaxel on pan-
creatic and PDAC organoids grown either in pure BME, fibrin 
+ 10% BME or fibrin/laminin. Again, no significant diffe rence 
could be observed between organoids grown in the diffe rent 
hydrogels (Figure S8, Supporting Information). Importantly, 
all tested human organoid lines could also be expanded and 
passaged repeatedly in the fibrin/laminin hydrogel (>6 passages 
tested for each line), suggesting that fibrin/laminin could be 
used as a universal alternative to BME for culturing organoids 
derived from different types of tissues.
Here we studied in detail how mouse small intestinal orga-
noids interact with their matrix, and used the data to establish a 
well-defined hydrogel that supports the long-term expansion of 
organoids derived from different mouse and human epithelial 
tissues. We found that fibrin is a suitable scaffold that could 
Adv. Mater. 2018, 30, 1801621
Figure 4. A) Mouse small intestinal stem cells four days after seeding in fibrin based hydrogels supplemented with Collagen IV, Heparin, Laminin, 
or in pure Matrigel. Morphology in brightfield microscopy. Scale bars: 200 µm. B) Quantification of the colony formation efficiency normalized to the 
Matrigel control. Error bars: SD, n = 4. C) Colony formation efficiency of mouse small intestinal stem cells seeded in fibrin gels supplemented with 
varying amounts of laminin or Matrigel. Error bars: SD, n = 6. D) Quantification of the changes in mechanical properties associated with the addition 
of Matrigel or laminin to fibrin hydrogels (3 mg mL−1), as measured by rheometry. Error bars: SD, n = 3.
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act as a physical substitute for BME. The mechanical as well 
as biochemical properties of the fibrin matrix are important 
parameters for organoid expansion, as increasing the stiffness 
of the gel or blocking the RGD domains in the scaffold inhib-
ited growth. We further found that the transition from spher-
ical organoids to budding organoids was associated with a shift 
of force distribution exerted on the matrix: while cystic orga-
noids applied uniform pressure on the matrix, in differentiated 
organoids pushing forces became predominantly restricted to 
the crypt-like domains and the core domains counteracted the 
internal pressure with increased contractility. Finally, we identi-
fied laminin as the major biological signaling molecule in BME 
that is required for organoid growth.
To our knowledge, the here developed fibrin/laminin 
hydrogel is the first well-defined 3D matrix that allows long-
term expansion of organoids containing both progenitor 
and differentiated cells. Recently, two independent studies 
described functionalized PEG-based hydrogels that also sup-
port the growth of intestinal progenitor cells in 3D in vitro.[22,23] 
Compared to BME, synthetic PEG hydrogels, however, have 
certain disadvantages. Gjorevski et al. reported the necessity of 
two different PEG hydrogels for intestinal organoid growth: a 
stiff nondegradable PEG gel that promotes intestinal stem cell 
expansion as spheroids, and a soft and hydrolyzing PEG gel 
that constrains stem cell proliferation but triggers differentia-
tion into the functional cell types of the intestinal epithelium. 
Adv. Mater. 2018, 30, 1801621
Figure 5. A) Mouse small intestinal organoids cultured long term in fibrin hydrogels supplemented with 2 mg ml−1 laminin. The organoids were stained 
for Goblet cells (PAS), Paneth cells (lysozyme), enteroendocrine cells (Chromogranin A), epithelial cells (E-Cadherin), and stem cells (Lgr5-GFP). 
Lgr5-positive and lysozyme positive cells were mostly observed in crypt-like domains. PAS and chromogranin positive were scattered throughout the 
organoids. The majority of organoids contained cells positive for the first three cell markers, whereas organoids containing chromogranin positive 
cells were less frequently observed. B) Various types of human epithelial organoids cultured > 6 passages in the fibrin/laminin hydrogels (left panel) 
and in Matrigel (right panel): human pancreas organoids, human pancreatic ductal adenocarcinoma organoids, human small intestinal organoids, 
and human liver organoids. C) Immunocytochemistry on human pancreas and liver organoids showing expression of the ductal marker cytokeratin 
19 (CK19). Scale bars A: 20 µm, B: 100 µm, C: 20 µm.
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The PEG-based hydrogel described by Cruz-Acuña et al. 
required initial expansion of pluripotent progenitor cells in 
2D cultures on a layer of BME, and differentiation of 3D sphe-
roids into functional intestinal epithelial cells was only demon-
strated after in vivo transplantation into mice. In addition, the 
expansion of human pluripotent stem cell-derived spheroids[23] 
required very different physical properties than the expansion 
of murine adult stem cell derived spheroids,[22] indicating that 
each PEG hydrogel formulation is limited to a narrow range of 
applicability. Indeed, when we reproduced the PEG hydrogel 
described by Cruz-Acuña et al., we found that it enabled growth 
of human liver and pancreas organoids, but did not support 
expansion of murine small intestinal organoids. The mor-
phology of human liver and pancreas organoids was moreover 
different than when grown in BME and fibrin/laminin 
(Figure S9, Supporting Information). Taken together, our data 
suggests that the fibrin/laminin gel has a broader range of 
applicability, and could be widely used to substitute BME for 
culturing organoids derived from different tissues.
The development of a defined fibrin-based hydrogel for orga-
noid growth opens novel possibilities for studying complex 
tissues in 3D in vitro. For example, the fibrin sites for factor 
XIII mediated covalent anchoring,[36] which we used here to 
couple fluorescent nanoparticles for 3D traction force micros-
copy, could also be used to directly anchor specific peptides or 
biomolecules, and to study their influence on cellular mecha-
nisms. In addition, the fibrin matrix could offer several advan-
tages for high-content drug screening in organoids compared 
to BME. First, it is relatively inexpensive, and using fibrin sup-
plemented with 10% BME instead of pure BME would there-
fore significantly reduce the costs of an organoid screening 
platform. Second, enzymatic gelation of fibrin offers advan-
tages over the thermoresponsive BME, as it does not require 
cooling of the liquid-handling robots. Finally, by demon-
strating a crucial role of laminin for organoid expansion, our 
work encourages the development of clinical-grade laminin, or 
laminin-subdomains that mimic its signaling function.[37] The 
latter might be necessary, as laminin is a large protein com-
plex prone to self-polymerization, making its production and 
purification particularly challenging. Importantly, since human 
fibrin is already commonly used as a tissue sealant in surgeries, 
these hydrogels could pave the way for the use of organoids in 
regenerative medicine to replace diseased epithelial tissues in 
patients with in vitro grown organoid epithelia.
Experimental Section
Mouse Tissues: All animal experiments were performed in accordance 
with protocols approved by the Kantonales Veterinäramt Zürich. 
Following mouse lines were used in this study: Lgr5-EGFP-IRES-creERT2 
(JAX 008875), CAG-eGFP (JAX 006567), C57BL/6J (JAX 000664).
Human Tissues: Human liver biopsies (ultrasound-guided needle 
biopsies) were obtained from the University Hospital Basel, human 
intestinal biopsies were obtained from the University Hospital Zürich, 
human pancreatic tissue was obtained from pancreatic islet isolation 
procedures from the University Hospital Zürich, human PDAC tissue 
was obtained from a previously established patient-derived xenograft 
(PDX) mouse model (Charles River Research Services Germany GmbH). 
Written informed consent was obtained from all patients, and the study 
was approved by the Cantonal Ethics committee of the north-western 
part of Switzerland and the Cantonal Ethics Committee of the Canton 
Zürich.
Organoid Isolation and Culturing: Mouse small intestinal organoids 
were isolated as previously described.[10] In short, the mouse small 
intestines was removed and flushed several times with phosphate 
buffered saline (PBS, Gibco, pH7.4). The small intestine was then 
placed in cold PBS, opened up longitudinally, and the villi were 
scraped off using a glass microscope slide. The intestine was cut into 
2–4 mm pieces and transferred into a 50 mL tube containing 10 mL 
of PBS. Subsequently the pieces were pipetted up and down and PBS 
replaced several times until the supernatant was clear. The supernatant 
was removed and the intestine pieces incubated in 25 mL of 2 × 10−3 m  
ethylenediaminetetraacetic acid (EDTA) in PBS on ice for 60 min. 
The solution was pipetted up and down several times, pieces were 
transferred into 10 mL PBS containing 10% fetal bovine serum (FBS), 
and the tube was shaken vigorously. The suspension was passed 
through 70 µm cell strainer (BD Biosciences), and centrifuged at 150 g. 
The pellet was then resuspended in growth factor reduced (GFR) 
Matrigel (Corning—lot numbers: 5257008, 7030565, 261008) at a 
density of ≈50–100 crypts per 20 µL. The solution was plated in 20 µL 
drops on prewarmed standard tissue culture plates (Greiner Bio-one), 
and after gelation at 37 °C small intestinal organoid medium containing 
10 × 10−6 m RhoKinase inhibitor (Y-27632, Abmole) was added. Mouse 
Small intestinal organoids were cultured at 37 °C in 5% CO2 in Advanced 
Dulbecco’s modified Eagle media (DMEM)/F12 (Gibco) supplemented 
with 10 × 10−3 m HEPES (Gibco), 1 × Glutamax (Gibco), 1% (or 
100 U per mL) Penicillin/Streptomycin (Gibco), 1 × N2 (Gibco), 1 × B27 
(Gibco), 1.25 × 10−3 m N-Acetylcysteine (Sigma), 5% in-house produced 
conditioned medium (CM) R-Spondin-1, 10% in-house produced CM 
Noggin, 50 ng mL−1 human EGF (Peprotech). Organoids were passaged 
either by mechanical dissociation using a fire-polished Pasteur pipette, 
or by incubation in TrypLE Express Enzyme (1x) (Gibco) for 10 min.
Human intestinal organoids were established from patient biopsies 
as described in van Wetering et al.[38] In short, the biopsies were placed 
in complete chelating solution (CCS) (5.6 × 10−3 m Na2HPO4, 8 × 10−3 m 
KH2PO4, 96.2 × 10−3 m NaCl, 1.6 × 10−3 m KCl, 43.4 × 10−3 m sucrose, 
and 54.9 × 10−3 m D-sorbitol). Dithiotreitol was added just before use to 
a final concentration of 0.5 × 10−3 m), as well as 2 × 10−3 m EDTA. The 
biopsies were then incubated for 20–45 min at 4 °C on a rocking plate. 
After incubation, tubes were shaken vigorously to liberate the crypts. 
Tissue fragments were allowed to settle for 1 min, and supernatant 
containing crypts was transferred to a new tube. One volume of FBS 
was added and crypts were spun down at 150 g for 3 min. Next, the 
crypts were washed twice with Advanced DMEM/F12 supplemented 
with 10 × 10−3 m HEPES, 1x Glutamax, 1% Penicillin/Streptomycin 
and finally spun down for 5 min at 150 g. The pellet was subsequently 
resuspended in GFR Matrigel, and plated in 20 µL drops on prewarmed 
standard tissue culture plates. After solidification of Matrigel, human 
small intestinal organoid medium containing 10 × 10−6 m RhoKinase 
inhibitor and 100 µg mL−1 Primocin (Invivogen) was added. Human 
small intestinal organoids were cultured in Advanced DMEM/F12 
supplemented with 10 × 10−3 m HEPES, 1x Glutamax, 1% Penicillin/
Streptomycin, 1x B27, 1.25 × 10−3 m N-acetylcysteine, 50% Wnt3a 
CM (produced in-house), 20% R-spondin-1 CM, 10% noggin CM, 
10 × 10−3 m nicotinamide (Sigma), 50 ng mL−1 human EGF, 10 × 10−9 m 
Gastrin (Tocris Bioscience), 0.5 × 10−6 m A83-01 (Tocris Bioscience) and 
10 × 10−6 m SB202190 (Sigma).
Human liver organoids were established from patient biopsies as 
described in Broutier et al.[39] Briefly, the biopsies were minced into 
pieces of roughly 0.5–1 mm and incubated in DMEM (Gibco) containing 
2.5 mg mL−1 collagenase D (Roche) and 0.1 mg mL−1 DNase I (Sigma) 
for 20–60 min at 37 °C on a shaker. The digestion was stopped by adding 
two volumes of ice cold DMEM containing 10% FBS and 1% Penicillin/
Streptomycin. Solution was filtered through a 70 µm nylon cell strainer. 
Residual liver was digested for 10 min with Accutase (Gibco) at 37 °C 
in the water-bath. Filtered solution was pelleted by 120 g centrifugation 
and resuspended in GFR Matrigel. Solution was plated in 20 µL drops 
on prewarmed standard tissue culture plates, and after gelation human 
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liver organoid medium containing 10 × 10−6 m RhoKinase inhibitor, 30% 
Wnt3a CM, and 10% Noggin CM was added. Human liver organoids 
were cultured in Advanced DMEM/F12 supplemented with 10 × 10−3 m 
HEPES, 1x Glutamax, 1% Penicillin/Streptomycin, 1x B27 without 
vitamin A (Gibco), 1x N2, 1.25 × 10−3 mN-acetylcysteine, 10 × 10−3 m 
nicotinamide, 50 ng mL−1 human EGF, 100 ng mL−1 FGF10 (Peprotech), 
25 ng mL−1 HGF (Peprotech), 10 × 10−9 m gastrin, 5 × 10−6 m A83-01, 
10 × 10−9 m prostaglandin E2 (Tocris Bioscience), 10 × 10−6 m forskolin 
(Tocris Bioscience), 10% R-Spondin-1 CM. Of note, noggin CM, Wnt3a 
CM, and RhoKinase inhibitor were only required in the first 3–4 days 
after the isolation.
Human pancreatic organoids were established from adult islet-
depleted pancreatic tissue[35] obtained from islet transplant programs. 
Briefly, pancreatic tissue was hand-picked to assure that no islets would 
be subcultured. Small clumps of pancreatic cells were obtained by 
mechanical dissociation of the islet-depleted pancreatic tissue with a 
fire-polished Pasteur pipette. After three washes with ice-cold PBS, the 
clumps were allowed to settle for 3 min on ice. The last washing step 
was carried out in cold Advanced DMEM/F12. The supernatant was 
removed and the clumps were embedded in 30–40 µL drops of GFR 
Matrigel at a density of ≈15–20 clumps in prewarmed standard 24-well 
tissue culture plates. After GFR Matrigel had solidified, human pancreas 
organoid medium with additional 10 × 10−6 m RhoKinase inhibitor and 
100 µg mL−1 Primocin (Invivogen) was added. The PDAC organoid line 
was derived from a previously established PDX PDAC line, which was 
obtained as single cell suspension, resuspended in Matrigel, and plated 
as 20 µL drops. Human Pancreas and human PDAC organoids were 
cultured in Advanced DMEM supplemented with 10 × 10−3 m HEPES, 
1x Glutamax, 1% Penicillin/Streptomycin, 1x N2, 1x B27, 1.25 × 10−3 m 
N-acetylcysteine, 50% Wnt3a CM, 10% R-spondin-1 CM, 10% noggin 
CM, 10 × 10−3 m nicotinamide, 50 ng mL−1 EGF, 10 × 10−9 m gastrin, 
100 ng mL−1 FGF10 and 0.5 × 10−6 m A83-01. Wild type pancreatic 
organoid medium was additionally substituted with 1 × 10−6 m 
prostaglandin E2.
Synthesis of Gel Precursors: FXIIIa cross-linkable PEG and HA were 
synthesized as described previously.[24,25] The protocol developed for HA 
modification with ≈10% substitution rate was applied to heparin, which 
is essentially identical in terms of chemical functionality, to obtain FXIIIa 
cross-linkable heparin. In short, 100 mg (0.168 mmol of the disaccharide 
repeat unit) of heparin (Sigma) and 5.95 mg (0.025 mmol) of 
3,3ʹ-dithiobis(propanoic dihydrazide) (DTPHY, Frontier Scientific) were 
dissolved in 10 mL of MES hydrate 150 × 10−3 m solution (resulting pH 
≈4.2). Then 9.6 mg (0.05 mmol) of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide were prediluted in 0.5 mL of water and added dropwise 
over stirring. The reaction was left to proceed for 6 h at room 
temperature and without stirring. Then the disulfides were reduced 
overnight in a closed flask by addition of 34.5 mg (0.15 mmol) of 
tricarboxyethylphosphine (TCEP-HCl, Fluorochem), prediluted in 0.5 mL 
of water. The product was supplemented with 1 g of NaCl, and dialyzed 
against ultrapure water. After recovery, the dialyzate was added dropwise 
over stirring to 0.25 mL (2.5 mmol) of divinylsulfone (DVS) prediluted 
in 5 mL of triethanolamine buffer, 300 × 10−3 m, pH 8.0. Divinylsulfone 
is lethal in contact with skin and should be handled with special care. 
The reaction was left to proceed overnight at room temperature without 
stirring. Then 1 g of NaCl was added and the product was dialyzed 
against ultrapure water again. Finally, 62 mg of glutamine donor 
peptides (sequence NQEQVSPLERCG, amidified carboxyterminus) were 
added, and the product was again dialyzed against diluted NaCl followed 
by ultrapure water, and lyophilized. To confirm successful conjugation 
of the modified heparin to fibrin gels, a fluorescein derivative was also 
synthesized by reacting the previous compound with 1/100th equivalents 
fluorescein isothiocyanate (FITC) over the disaccharide repeat unit 
(which is ≈1/10th over the peptides, which provide free amino groups 
for conjugation at their aminoterminus). The conjugation was done in 
sodium hydrogen carbonate buffer, 100 × 10−3 m, pH 9.5, for 5 h at room 
temperature, and the product dialyzed and lyophilized.
Fibrin Gelation: Organoids were resuspended in 3 mg mL−1 fibrinogen 
(Tisseel, Baxter) and 0.1% nanocellulose (Growdex, UPM) in PBS 
containing 0.9 × 10−3 m CaCl2 and 0.49 × 10−3 m MgCl2. Depending on 
the experiment, the suspension was supplemented with 10% v/v GFR 
Matrigel (Corning) or 0.5–2 mg mL−1 laminin (Corning #354259) or 
0.5 mg mL−1 human collagen IV (Sigma) or FXIIIa-cross-linkable heparin. 
Polymerization was induced by the addition of 0.5 U per mL thrombin 
and left to proceed for 30 min at 37 °C in a humidified incubator before 
adding culture medium. Fibrinogen and thrombin were prewarmed to 
37 °C before use, all other components were kept at 4 °C before adding. 
The nanofibrillar cellulose is biologically inert and was only used to 
increases the viscosity during gelation in order to avoid sedimentation of 
organoids. The cellulose was not included in traction force microscopy 
measurements to avoid creating mechanical inhomogeneities, instead 
the gels were flipped during gelation to avoid sedimentation. Individual 
gels were ≈20 µL in volume, and could be formed and cultured equally 
well either as droplets at the bottom of 24 well-plates (for expansion), of 
a glass bottom plates (for imaging from bottom), or in 4 mm diameter x 
1 mm height PDMS (Sylgard 184) molds adsorbed on 10 mm diameter 
coverslips (for easier handling during incubations and transfers as well 
as for imaging from the top).
HA Gelation: Dissociated organoids were resuspended in a 0.4% w/v 
transglutaminase cross-linkable HA solution in a buffer consisting of 
Tris 50 × 10−3 m, CaCl2 50 × 10−3 m, glucose 100 × 10−3 m, pH 7.6. The 
solution was then supplemented with FXIIIa 10 U per mL from a 200 U 
per mL stock (Fibrogammin, CSL Behring), distributed in silicon molds 
and left to gel for 30 min at 37 °C. Where applicable, 10% of the buffer 
was replaced by Matrigel.
PEG Gelation: Dissociated organoids were resuspended in a 1.2% w/v 
solution of TG cross-linkable 40 kDa 8-arm-PEG, in a buffer consisting of 
Tris buffer 50 × 10−3 m, CaCl2 50 × 10−3 m, NaCl 50 × 10−3 m, with pH7.6 
and supplemented last moment with 10 U per mL FXIIIa from a 200 U 
per mL stock. The solution was pipetted into silicon molds, and gelation 
was left to proceed for 30 min at 37 °C. Where applicable, 10% of the 
buffer was replaced by Matrigel.
Alginate Gelation: Dissociated organoids were resuspended in a 
0.15% w/v alginate solution (Novamatrix, high viscous) in cell culture 
medium. The solution was added to silicon molds. Then, the gel 
cylinders were covered with a cellulose membrane pre-wetted with a 
10 × 10−3 m calcium chloride solution in medium, and an additional 
100 µL of calcium solution was added on top. The gelation was left to 
proceed for 1 h at 37°. Where applicable, 10% of the buffer was replaced 
by Matrigel.
Matrigel Gelation: Dissociated organoids were resuspended in 
Matrigel, plated in 20 µL drops or pipetted in silicon molds, and gelled 
at 37 °C for 10 min.
Quantification of Intestinal Stem Cell Colony Formation Efficiency: 
Organoids were digested for 5 min at 37 °C using TrypLE and 
resuspended in the different hydrogels in silicon molds. After 3 or 
4 days (see figure legends) the whole gels were imaged in brightfield 
(Zeiss observer) and the number of growing organoids was quantified 
manually. When applicable, the organoids size was quantified using 
manual segmentation in Fiji.
Rheological Measurements: The storage moduli of the hydrogels 
were determined with small-strain oscillatory shear measurements on 
a Physica MCR 301 rheometer (Anton-Paar) using a 20 mm diameter 
parallel plate geometry. The gels were formed in situ and gelation 
monitored with 20 s steps using oscillations at 1 Hz and 5% strain. 
For Cultrex BME2, Matrigel, and laminin, which are thermoresponsive, 
the rheometer was precooled to 4 °C and the temperature was set to 
37 °C after 3 min of measurement. For PEG, HA, fibrin, y, which are 
enzymatically cross-linked, the rheometer was prewarmed to 37 °C 
and the enzyme was added and mixed swiftly immediately before the 
measurement. For alginate, a 10 mm parallel plate geometry was used 
instead, and the calcium solution was added all around the precursor/
probe immediately after starting the measurement. All buffers, polymers, 
and enzyme concentrations were the same as described above.
Immunohistochemistry of Intestinal Organoids: Organoids were fixed 
for 2 h with 4% paraformaldehyde and subsequently embedded into 
paraffin using standard protocols. 4 µm tissue sections were stained. 
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Primary antibodies used: E-cadherin (BD 610182, 1:1000), lysozyme 
(Dako, A009902, 1:1750), chromogranin A (Santa Cruz, SC-13090, 
1:200). Secondary antibodies were used 1:1000: Thermo-Fisher 
Scientific, Donkey anti-Rabbit Alexa Fluor 568 (A10042), or Donkey 
anti-Mouse Alexa Fluor 488 (A21202). For periodic acid Schiff staining 
(Sigma-Aldrich, 395B-1KT) and H&E staining, standard protocols were 
used.
Immunocytochemistry of Pancreas and Liver Organoids: Organoids 
were fixed and permeabilized for 2 h with 4% paraformaldehyde and 
0.1% triton-X100 in PBS, blocked with 5% bovine serum albumin (BSA) 
in PBS overnight. The gels were then broken down by gentle pipetting, 
and the gel fragments were re-embedded in fibrin at 6 mg mL−1 in 5 µL 
droplets on a glass bottom 96 well plate. All the antibody incubations 
and PBS washes were done overnight. Antibodies, diluted in 5% BSA 
solution, were: E-cadherin (BD 610182, 1:1000), Ki67 (Abcam 15580, 
1:300), CK-19 (Abcam 52625, 1:600), SOX-9 (Millipore 5535, 1:1000), 
HNF-4α (Santa-Cruz H-171, 1:1000), β-catenin (Abcam 32572, 1:200), 
goat anti-mouse IgG Alexa-594 (Invitrogen, 1:500), goat anti-rabbit IgG 
Alexa-488 (Invitrogen, 1:500).
RGD Competition Assay: Organoids dissociated with TrypLE and 
freshly plated in the applicable gels were incubated either in mouse 
small intestinal growth medium or small intestinal growth medium 
supplemented with 0.1 × 10−3 m RGD peptides (Anaspec, sequence 
Ac-GCGYGRGDSPG-NH2).
RGD Loading Assay: The method used was developed by Schense and 
Hubbell.[40] Factor XIIIa cross-linkable RGD-containing peptides with the 
sequence NQEQVSPLRGDSPG-NH2 were synthesized with classical 
solid-phase supported fmoc peptide synthesis on a Protein Technologies 
Prelude instrument and purified by reverse-phase (C18-silica) preparative 
high performance liquid chromatography (HPLC) on an Agilent Infinity 
1260 instrument using a gradient of 10%–90% acetonitrile in water 
with 0.1% trifluoroacetic acid (TFA). Peptide identity was confirmed 
by mass-spectroscopy (1483 g mol−1). The peptides were lyophilized, 
resuspended in ultrapure water, neutralized with dilute NaOH, sterilized 
by filtration at 0.2 µm, aliquoted and relyophilized for prolonged storage.
The peptides were mixed at 200 and 400 × 10−6 m from 2 × 10−3 m 
reconstituted PBS stocks in the fibrin 3 mg mL−1 + 10% Matrigel gels, 
and trypsinized mouse small intestinal organoid cells were encapsulated 
as described above. The medium was changed after 1, 3, and 12 h in 
order to wash unbound peptides, and the colony formation efficiency 
and morphology were observed after 4 d in culture from brightfield 
imaging (Zeiss Observer, 5x objective).
For peptide coupling quantifications, gels of 50 µL were formed in 
200 µL tubes, as well as equivalent dilutions of peptides in PBS serving 
as standards. 50 µL of PBS was then added to each tube, and let the 
free peptide diffuse to equilibrium over 24 h. 10 µL of the solution was 
collected from each tube to analyze the percentage of free peptide in 
standards and in gel supernatants by analytical reverse-phase HPLC. The 
percentage of missing peptide (consistently found to be 14%–15%) was 
used to calculate the molarity of coupled RGD peptides.
The total amount of RGD peptides in the gels were calculated using 
reported values of two RGD sequences per fibrinogen alpha chain,[41] 
hence four RGD per fibrinogen 340 kDa hexamer. In Matrigel, RGD 
concentration was estimated using manufacturer’s reported values of 
9 mg mL−1 solid content including 60% of the 800 kDa laminin, which 
has one RGD site.
Hydrogel Microstructure Imaging: 15 µL hydrogel drops were placed 
in silicone molds on coverslips and gelled as described previously. After 
gelation, the hydrogels were covered with Advanced DMEM (Gibco) 
supplemented with 10 × 10−3 m HEPES, and incubated at 37 °C for 
16 h. The gels were then washed three times for 20 min with PBS, and 
incubated with F-NHS (Thermo 46410) in PBS (1:120 dilution of a 1% w/v 
frozen stock in DMSO) for 2 h and finally washed 3 × 30 min with PBS. 
The hydrogels were imaged on a Leica TCS SP8 confocal microscope.
Fluorescent Nanoparticle Functionalization: 40 µL of 40 nm fluorescent 
polystyrene nanoparticle (nP) solution (Thermo F8793) was reacted 
in 100 × 10−3 m MES buffer, pH 4.5, with 40 µL of EDC 10 × 10−3 m 
and 40 µL of DTPHY 10 × 10−3 m. The reaction was left to proceed for 
1 h. Then 1 mg of TCEP was added for reduction, which resulted in 
immediate nanoparticle precipitation. The particles could be redispersed 
by adding 500 µL of 1% sodium dodecyl sulfate (SDS) in water with 
sonication. The reaction byproducts were removed by repeated dilution 
in 1% SDS in water and reconcentration with a 100 kDa MWCO 
Vivaspin protein concentrator (2500 g, 10 min). 500 µL of nanoparticle 
suspension were recovered, and 10 µL of DVS prediluted in 500 µL of 
triethanolamine buffer, 300 × 10−3 m, pH 8.0, was added. The reaction 
was left to proceed for 10 min at RT, before washing and reconcentrating 
with the centrifugal filter. Finally, 2 mg of TG peptide NQEQVSPL-ERCG 
was dissolved in 500 µL of the triethanolamine buffer and added, left to 
react for 30 min at 37 °C, and the final TG-cross-linkable nanoparticles 
(nP-TG) product was isolated by washing first with tris buffered saline 
pH7.5 (TBS), and then with TBS + 0.1% BSA. The BSA was used here as 
a cytocompatible surfactant that can keep the modified nanoparticles in 
stable suspension. The resulting nP-TG stock was filtered at 0.2 µm and 
stored in the fridge for up to a few months.
Organoid Culture for Force Sensing Experiments: Mouse small intestinal 
organoids expressing GFP insert were dissociated with TrypLE and 
resuspended in a fibrin gels solution supplemented with Matrigel 
and modified with fluorescent nanoparticles (3 mg mL−1 Fibrin, 0.5 U 
per mL Thrombin, 10% to 40% v/v Matrigel, 0.5 U per mL thrombin, 5% 
v/v nP-TG stock, in calcium containing PBS). Eight well glass bottom 
plates (Ibidi µ-Slide) were prepared by placing a single silicone mold in 
each well. 15 µL of the organoid/hydrogel suspension were placed in 
each mold and incubated for 30 min at 37 °C. Subsequently, full mouse 
small intestinal growth medium was added and the cells incubated at 
37 °C, 5% CO2 for 1–5 days.
3D Traction Force Microscopy: The organoids were live-imaged with 
a 40 x water immersion objective and a white light laser providing 
simultaneous excitation at 488 and 594 nm, on a Leica SP8 confocal 
microscope equipped with CO2 and prewarmed to 37 °C for typically 
12 h (to stabilize from temperature-induced drifting). 0.2% sodium 
azide was added to the media from a 10% w/v stock, and the organoids 
were left to die for 2 h. The same positions were then imaged again as a 
relaxed reference.
The scripts used for force reconstruction from such images 
are provided on GitHub together with a user manual as well as 
extensively commented code (https://github.com/nbroguiere/TFM). 
No programming knowledge is needed to use this code, but basic 
understanding of mechanics and image analysis can be helpful in 
adjusting the parameters. In short, a cubic lattice was used with 
10 µm spacing, and tracked the displacement of a 20 µm wide cubic box 
between the live and dead images on each position of this lattice using 
normalized cross-correlation with subpixel accuracy. Only normalized 
cross-correlation values above 0.7, which indicate a good match, 
were kept for further consideration. This provided an experimental 
displacement field. The organoids were also segmented from the GFP 
channel, and the position of the organoid was used to define the borders 
for the mechanics calculations. A fitted displacement field was then 
reconstructed by solving a minimization problem. More precisely, the 
quadratic distance between the experimental displacement field and the 
fitted displacement field was minimized under the constraint that forces 
are restricted to the cell surface and edges of the imaged area (using 
a penalty on forces in the minimization problem infinitesimal on the 
surfaces and very large in the matrix, such as 10−9 and 10−9 relative to 
the penalty on the displacement fit, for appropriately adimensionalized 
displacements and forces). A smoothing parameter was also included in 
the minimization to favor continuity of the forces. Using the fitted 
displacement field, all nine components of the stress tensor were 
computed on every position of the cubic mesh. The shear modulus 
experimentally measured for the fibrin + 10% Matrigel matrix (70 Pa) 
was used for these calculations. The stress tensor on the cell surface was 
then interpolated between these discrete positions using a Gaussian 
weighted average. The surface of the cell was finally meshed, which 
provided the normal vector on every point of the cell surface, and the 
normal pressure on this mesh was defined as [normal vector]t × [stress 
tensor] × [normal vector], and displayed as a color-code in the final figure.
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Cultures of FACS Isolated Stem Cells: Lgr5-GFP and wild type mouse 
small intestinal organoids cultured in medium supplemented with 
valproic acid (VPA) and CHIR99021 (for stem cell enrichment as 
described by Yin et al.[42]) were collected. Matrigel was removed by 
washing twice in ice-cold Advanced DMEM/F12, followed by 7 min 
digestion with TrypLE. The cell suspensions were filtered through a 
40 µm mesh. Cells were stained with 4′,6-diamidino-2-phenylindole 
(DAPI) shortly before acquisition. Fluorescence-activated cell-sorting 
(FACS) was performed using FACS Aria III (BD, Franklin Lakes, NJ, 
USA). DAPI negative, GFP positive cells were collected, pelleted 
by centrifugation, and resuspended in fibrin 3 mg mL−1 + laminin 
2 mg mL−1 gels for plating and culturing as described previously.
PEG-Maleimide+RGD Hydrogels: The gels were formed with the 
protocols of Cruz-Acuña et al.,[23] using identical reagents and suppliers.
Gene Expression: Gene expression was quantified from human 
pancreas and liver organoids cultured in Matrigel or in fibrin 
3 mg mL−1 + laminin 2 mg mL−1. HEK cells were used as a control. For 
each condition, four hydrogels of 20 µL (or 500 000 HEK cells) were 
collected, and pelleted by centrifugation at 2000 g for 1.5 min. After 
removing the excess media, samples were frozen at −80 °C until use. 
After addition of lysis buffer, samples were homogenized by repeated 
pipetting and RNA was isolated using NucleoSpin miRNA kit (Macherey–
Nagel) following manufacturer’s instructions. The RNA concentration 
was determined with a plate reader (Synergy H1, BioTek Instruments). 
RNA with an absorbance ratio at 260/280 nm between 1.9 and 2.1 was 
used for quantitative polymerase chain reaction (qPCR) analysis. The 
Fast SYBR Green Master Mix (Applied Biosystems) was used to perform 
the PCR amplification with 150 × 10−9 m forward and reverse primer. 
Data were analyzed using the 2−ΔΔCt method and normalized against the 
house-keeping gene GAPDH and the HEK controls.
Organoid Drug Assay using Defined Hydrogels: Human wildtype 
pancreas and PDAC organoid lines were dissociated and seeded in 
four replicates in 5 µL drops of hydrogels (Matrigel; 3 mg mL−1 fibrin + 
10% Matrigel; 3 mg mL−1 fibrin + 2 mg mL−1 laminin) in 96 well black 
plates with clear bottom (Corning). Plates were incubated for 10 min in 
37 °C and 5% CO2 cell culture incubator to allow solidification of the 
gels. The hydrogel droplets were then overlaid with 100 µL of complete 
organoid media containing either DMSO 0.1%, Gemcitabine 1 × 10−6 m 
(Selleckchem) or Paclitaxel 1 × 10−6 m (Selleckchem). 72 h post seeding 
pictures were taken with a Zeiss Apotome, and Cell Titer Glo 3D 
measurements (Promega) were performed according to manufacture 
instructions. Luminescence readings were acquired with the Synergy H1 
reader (BioTek).
Statistical Analysis: Statistically significant differences in colony 
formation efficiency/colony area/drug responses were assessed by 
a one-way analysis of variance (ANOVA) test followed by a Sidak’s 
post-hoc test in Graphpad Prism 7.02 when the ANOVA p-value is under 
0.05. p-values under 0.05 were considered significant. The annotations 
on graphs are: ns = not significant, * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, **** = p < 0.0001. When only two conditions were present, 
Student’s t-tests were used. p-values from repeated measures ANOVA 
were used to compare the overall gene expression in Matrigel versus 
Fibrin/Laminin.
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